NO311354B1 - Kreatinpyruvater og fremgangsmåte for fremstilling av disse - Google Patents
Kreatinpyruvater og fremgangsmåte for fremstilling av disse Download PDFInfo
- Publication number
- NO311354B1 NO311354B1 NO19992603A NO992603A NO311354B1 NO 311354 B1 NO311354 B1 NO 311354B1 NO 19992603 A NO19992603 A NO 19992603A NO 992603 A NO992603 A NO 992603A NO 311354 B1 NO311354 B1 NO 311354B1
- Authority
- NO
- Norway
- Prior art keywords
- creatine
- pyruvate
- pyruvic acid
- creatine pyruvate
- anion
- Prior art date
Links
- CVSVTCORWBXHQV-UHFFFAOYSA-N anhydrous creatine Natural products NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 229960003624 creatine Drugs 0.000 title claims abstract description 31
- 239000006046 creatine Substances 0.000 title claims abstract description 31
- -1 Creatine pyruvates Chemical class 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims 5
- 238000002360 preparation method Methods 0.000 title description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims abstract description 44
- 229940107700 pyruvic acid Drugs 0.000 claims abstract description 22
- 238000006243 chemical reaction Methods 0.000 claims abstract description 6
- 208000008589 Obesity Diseases 0.000 claims abstract description 4
- 206010033307 Overweight Diseases 0.000 claims abstract description 4
- 235000020824 obesity Nutrition 0.000 claims abstract description 4
- 208000028867 ischemia Diseases 0.000 claims abstract description 3
- 210000000577 adipose tissue Anatomy 0.000 claims abstract 2
- DLNGCCQFGNSBOP-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.NC(=N)N(C)CC(O)=O DLNGCCQFGNSBOP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 10
- 229940076788 pyruvate Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000019449 other food additives Nutrition 0.000 claims 1
- 230000002000 scavenging effect Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- 230000006735 deficit Effects 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000002516 radical scavenger Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 229960004826 creatine monohydrate Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 150000004728 pyruvic acid derivatives Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229940018333 calcium pyruvate Drugs 0.000 description 1
- UZWMCCLZMHPPKW-UHFFFAOYSA-L calcium;2-oxopropanoate Chemical compound [Ca+2].CC(=O)C([O-])=O.CC(=O)C([O-])=O UZWMCCLZMHPPKW-UHFFFAOYSA-L 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- JKVUQLWTIZFTMF-UHFFFAOYSA-M potassium;2-oxopropanoate Chemical compound [K+].CC(=O)C([O-])=O JKVUQLWTIZFTMF-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
- C07C59/19—Pyruvic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Extrusion Moulding Of Plastics Or The Like (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19653225A DE19653225A1 (de) | 1996-12-20 | 1996-12-20 | Kreatin-pyruvate und Verfahren zu deren Herstellung |
US08/893,423 US6166249A (en) | 1996-12-20 | 1997-07-11 | Creatine pyruvates |
PCT/EP1997/007121 WO1998028263A1 (de) | 1996-12-20 | 1997-12-18 | Kreatin-pyruvate und verfahren zu deren herstellung |
Publications (3)
Publication Number | Publication Date |
---|---|
NO992603D0 NO992603D0 (no) | 1999-05-31 |
NO992603L NO992603L (no) | 1999-05-31 |
NO311354B1 true NO311354B1 (no) | 2001-11-19 |
Family
ID=26032506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19992603A NO311354B1 (no) | 1996-12-20 | 1999-05-31 | Kreatinpyruvater og fremgangsmåte for fremstilling av disse |
Country Status (23)
Country | Link |
---|---|
US (1) | US6172111B1 (ja) |
EP (1) | EP0894083B1 (ja) |
JP (1) | JP3090960B2 (ja) |
CN (1) | CN1076343C (ja) |
AT (1) | ATE186295T1 (ja) |
AU (1) | AU727524B2 (ja) |
BG (1) | BG63537B1 (ja) |
BR (1) | BR9711954A (ja) |
CA (1) | CA2255665C (ja) |
CZ (1) | CZ293282B6 (ja) |
DE (1) | DE59700666D1 (ja) |
DK (1) | DK0894083T3 (ja) |
ES (1) | ES2139465T3 (ja) |
GR (1) | GR3031754T3 (ja) |
HK (1) | HK1020718A1 (ja) |
IL (1) | IL127148A (ja) |
NO (1) | NO311354B1 (ja) |
NZ (1) | NZ332830A (ja) |
PL (1) | PL330279A1 (ja) |
RU (1) | RU2179970C2 (ja) |
SK (1) | SK283195B6 (ja) |
TR (1) | TR199900470T2 (ja) |
WO (1) | WO1998028263A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1051914A1 (de) * | 1999-05-08 | 2000-11-15 | DSM Fine Chemicals Austria GmbH | Verwendung von Kreatin als Futterzusatz |
US6242491B1 (en) * | 1999-06-25 | 2001-06-05 | Rima Kaddurah-Daouk | Use of creatine or creatine compounds for skin preservation |
DE19929995B4 (de) | 1999-06-30 | 2004-06-03 | Skw Trostberg Ag | Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen |
AU6153200A (en) * | 1999-06-30 | 2001-01-22 | Skw Trostberg Aktiengesellschaft | Use of creatine and/or creatine derivatives for treating feelings of ill-health in women |
DE10003835A1 (de) * | 2000-01-28 | 2001-08-16 | Sueddeutsche Kalkstickstoff | Formulierungen bei Dehydratationszuständen |
EP1688139A1 (en) * | 2000-09-14 | 2006-08-09 | Board of Regents of the University of Nebraska | Creatine ester pronutrient compounds and formulations |
US20030212136A1 (en) | 2001-09-14 | 2003-11-13 | Vennerstrom Jonathan L. | Creatine ester pronutrient compounds and formulations |
DE10064312C2 (de) * | 2000-12-22 | 2003-05-22 | Degussa | Cholinpyruvat-Hydrat, Verfahren zu dessen Herstellung, Cholinpyruvat-Hydrat enthaltende Formulierung sowie deren Verwendung |
US6838562B2 (en) * | 2003-04-01 | 2005-01-04 | Sal Abraham | Process for preparing a creatine heterocyclic acid salt and method of use |
DE10355716A1 (de) | 2003-11-26 | 2005-06-23 | Beiersdorf Ag | Kosmetische Zubereitungen mit einem Gehalt Kreatin und/oder Kreatinderivaten und/oder Kreatinin und/oderKreatininderivaten und organischen Verdickern |
DE502005002355D1 (de) | 2004-06-09 | 2008-02-07 | Evonik Degussa Gmbh | Guanidinoessigsäure als futtermittelzusatz |
DE102006031441B4 (de) * | 2006-07-05 | 2011-12-29 | Hans Matt | Orales Creatin-Supplement, sowie Verfahren zur Herstellung desselben |
DE102007004781A1 (de) | 2007-01-31 | 2008-08-07 | Alzchem Trostberg Gmbh | Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels |
DE102007030495A1 (de) | 2007-06-30 | 2009-01-15 | Alzchem Trostberg Gmbh | Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der Gedächtnisleistung, der Merkfähigkeit, des Langzeitgedächtnisses und zur Vorbeugung geistiger Ermüdungszustände |
DE102007053369A1 (de) | 2007-11-09 | 2009-07-02 | Alzchem Trostberg Gmbh | Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der männlichen Fruchtbarkeit |
DE102007062288A1 (de) | 2007-12-21 | 2009-06-25 | Alzchem Trostberg Gmbh | Kreatin-Zubereitung und Verfahren zu deren Herstellung |
US20110123654A1 (en) * | 2008-06-06 | 2011-05-26 | Ralf Jaeger | Synergistic enhancement of cellular ergogenic nutrient uptake, like creatine or carnitine, with tarragon |
US8466198B2 (en) * | 2008-09-02 | 2013-06-18 | Bruce Kneller | Compositions comprising creatine salts and methods of use thereof |
WO2011090676A1 (en) | 2009-12-29 | 2011-07-28 | Hill's Pet Nutrition, Inc. | Compositions including pyruvate for companion animals and methods of use thereof |
AU2014280235B2 (en) | 2013-06-12 | 2019-10-03 | Anabio Technologies Limited | A process for producing microcapsules comprising an active component encapsulated, protected and stabilised within a protein shell |
CN111935990A (zh) | 2018-03-27 | 2020-11-13 | 赢创运营有限公司 | 胍乙酸和/或肌酸在水产养殖中的用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1967400A (en) * | 1930-03-27 | 1934-07-24 | Schering Kahlbaum Ag | Production of guanidino fatty acids |
FR4508M (ja) * | 1965-05-06 | 1966-10-17 | ||
US4548937A (en) * | 1981-04-01 | 1985-10-22 | Montefiore Hospital | Method for preventing body fat deposition in mammals |
ATE22655T1 (de) * | 1982-11-10 | 1986-10-15 | Laevosan Gmbh & Co Kg | Infusionsloesungen zur herztherapie. |
US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
GB9215746D0 (en) * | 1992-07-24 | 1992-09-09 | Hultman Eric | A method of increasing creatine supply depot |
JP3213666B2 (ja) * | 1994-02-28 | 2001-10-02 | 治彦 末岡 | クレアチン飲料の製造方法 |
US5627172A (en) * | 1994-03-04 | 1997-05-06 | Natural Supplement Association, Incorporated | Method for reduction of serum blood lipids or lipoprotein fraction |
US5536751A (en) * | 1994-05-09 | 1996-07-16 | The United States Of America As Represented By The Secretary Of The Army | Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof |
IT1271687B (it) * | 1994-08-04 | 1997-06-04 | Flamma Spa | Sali organici idrosolubili della creatina |
US5886040A (en) * | 1997-06-17 | 1999-03-23 | Amt Labs, Inc. | Creatine pyruvate salt with enhanced palatability |
-
1997
- 1997-12-18 PL PL97330279A patent/PL330279A1/xx unknown
- 1997-12-18 DK DK97954423T patent/DK0894083T3/da active
- 1997-12-18 CZ CZ19983626A patent/CZ293282B6/cs not_active IP Right Cessation
- 1997-12-18 RU RU98122207/04A patent/RU2179970C2/ru not_active IP Right Cessation
- 1997-12-18 DE DE59700666T patent/DE59700666D1/de not_active Expired - Fee Related
- 1997-12-18 SK SK1556-98A patent/SK283195B6/sk unknown
- 1997-12-18 NZ NZ332830A patent/NZ332830A/xx unknown
- 1997-12-18 CA CA002255665A patent/CA2255665C/en not_active Expired - Fee Related
- 1997-12-18 WO PCT/EP1997/007121 patent/WO1998028263A1/de active IP Right Grant
- 1997-12-18 BR BR9711954A patent/BR9711954A/pt not_active IP Right Cessation
- 1997-12-18 CN CN97195889A patent/CN1076343C/zh not_active Expired - Fee Related
- 1997-12-18 AT AT97954423T patent/ATE186295T1/de not_active IP Right Cessation
- 1997-12-18 ES ES97954423T patent/ES2139465T3/es not_active Expired - Lifetime
- 1997-12-18 JP JP10528354A patent/JP3090960B2/ja not_active Expired - Lifetime
- 1997-12-18 TR TR1999/00470T patent/TR199900470T2/xx unknown
- 1997-12-18 AU AU58576/98A patent/AU727524B2/en not_active Ceased
- 1997-12-18 IL IL12714897A patent/IL127148A/en not_active IP Right Cessation
- 1997-12-18 EP EP97954423A patent/EP0894083B1/de not_active Expired - Lifetime
-
1998
- 1998-11-18 BG BG102932A patent/BG63537B1/bg unknown
-
1999
- 1999-05-12 US US09/310,323 patent/US6172111B1/en not_active Expired - Fee Related
- 1999-05-31 NO NO19992603A patent/NO311354B1/no not_active IP Right Cessation
- 1999-11-04 GR GR990402819T patent/GR3031754T3/el unknown
- 1999-12-09 HK HK99105752A patent/HK1020718A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1020718A1 (en) | 2000-05-19 |
CA2255665A1 (en) | 1998-07-02 |
NO992603D0 (no) | 1999-05-31 |
DE59700666D1 (de) | 1999-12-09 |
CA2255665C (en) | 2002-05-14 |
CZ293282B6 (cs) | 2004-03-17 |
BG63537B1 (bg) | 2002-04-30 |
CN1224416A (zh) | 1999-07-28 |
EP0894083B1 (de) | 1999-11-03 |
NO992603L (no) | 1999-05-31 |
ATE186295T1 (de) | 1999-11-15 |
BR9711954A (pt) | 1999-08-24 |
JP3090960B2 (ja) | 2000-09-25 |
US6172111B1 (en) | 2001-01-09 |
CN1076343C (zh) | 2001-12-19 |
AU727524B2 (en) | 2000-12-14 |
JPH11509560A (ja) | 1999-08-24 |
ES2139465T3 (es) | 2000-02-01 |
DK0894083T3 (da) | 2000-04-03 |
GR3031754T3 (en) | 2000-02-29 |
SK155698A3 (en) | 1999-05-07 |
AU5857698A (en) | 1998-07-17 |
EP0894083A1 (de) | 1999-02-03 |
TR199900470T2 (xx) | 1999-06-21 |
PL330279A1 (en) | 1999-05-10 |
CZ362698A3 (cs) | 1999-03-17 |
WO1998028263A1 (de) | 1998-07-02 |
RU2179970C2 (ru) | 2002-02-27 |
SK283195B6 (sk) | 2003-03-04 |
IL127148A (en) | 2002-11-10 |
NZ332830A (en) | 2000-04-28 |
BG102932A (en) | 1999-09-30 |
IL127148A0 (en) | 1999-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO311354B1 (no) | Kreatinpyruvater og fremgangsmåte for fremstilling av disse | |
US6166249A (en) | Creatine pyruvates | |
US5863939A (en) | Creatine ascorbates and a method of producing them | |
WO2006028068A1 (ja) | L-カルニチンの精製方法 | |
JPWO2006001345A1 (ja) | L−リジン・クエン酸塩結晶 | |
JP5080496B2 (ja) | 酸性プロピオン酸塩の製造 | |
US6203827B1 (en) | Composition containing readily absorbable calcium and process for producing the same | |
US6232497B1 (en) | Method for producing alkali metal and alkaline earth metal pyruvates | |
JP2006265202A (ja) | α−リポ酸アミノ酸塩 | |
US20050037069A1 (en) | Solid and stable creatine/citric acid composition(s) and compositions carbohydrate(s) or hydrates thereof, method for the production and use thereof | |
US7026507B2 (en) | Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate | |
US5962734A (en) | Method of producing calcium pyruvates | |
CA2296017A1 (en) | Method for producing calcium pyruvates | |
CA1290761C (en) | Chemical complex of potassium acetylsalicylate and preparation thereof | |
MXPA98010488A (en) | Creatine pyruvates and method for their production | |
GB2344996A (en) | A solid stable aggregate formed from a pyruvate component and a carbohydrate component | |
KR20000016221A (ko) | 크레아틴 피루베이트 및 이의 제조 방법 | |
CN109761801B (zh) | 一种酮缬氨酸钙的制备新方法 | |
EP3981759A1 (en) | New crystal form of treprostinil sodium salt and preparation method therefor | |
KR100461572B1 (ko) | L-카르니틴 칼슘 염과 이의 제조방법 | |
MXPA99011864A (en) | Method for producing calcium pyruvates | |
CN113425614A (zh) | 氨基酸或氨基酸类似物或其盐在作为提高尿囊素溶解性能的添加剂的应用 | |
CZ457499A3 (cs) | Způsob výroby vápenatých pyruvátů | |
RU2003118625A (ru) | Способ получения желейного мармелада | |
WO2005076747A2 (en) | Double salts of (-)-hydroxycitric acid with an amine and a group ii a metal and a process for preparing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN JUNE 2002 |